Glenmark Pharmaceuticals Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

According to the company?s exchange filing, the inspection was conducted between 24 November and 28 November 2025.

Glenmark Pharmaceuticals is engaged in the business of development, manufacturing, and marketing of pharmaceutical products, both formulations and active pharmaceutical ingredients, to regulated and semi-regulated markets.

Glenmark Pharmaceuticals, the company, reported a 72.3% jump in consolidated net profit to Rs 610.25 crore on a 76.6% increase in revenue from operations to Rs 6,003.79 crore in Q2 FY25.

The counter rose 0.01% to Rs 1,947.35 on the BSE.

Powered by Capital Market - Live News

Glenmark Pharmaceuticals announced that the U.S. Food and Drug Administration (U.S. FDA) completed Pre-Approval Inspection at the Company's formulations manufacturing facility in Chhatrapati Sambhajinagar (Aurangabad). The inspection was carried out from 24 November to 28 November 2025, and concluded with zero 483 observations.

Powered by Capital Market - Live News

Glenmark Pharmaceuticals Ltd is up for a third straight session today. The stock is quoting at Rs 1941, up 1.03% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.18% on the day, quoting at 26251.5. The Sensex is at 85859.63, up 0.29%. Glenmark Pharmaceuticals Ltd has gained around 6.94% in last one month.

Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has gained around 2.75% in last one month and is currently quoting at 22862.35, down 0% on the day. The volume in the stock stood at 9.89 lakh shares today, compared to the daily average of 12.05 lakh shares in last one month.

The benchmark December futures contract for the stock is quoting at Rs 1952, up 0.86% on the day. Glenmark Pharmaceuticals Ltd is up 29.82% in last one year as compared to a 9.77% jump in NIFTY and a 5.22% jump in the Nifty Pharma index.

The PE of the stock is 36.84 based on TTM earnings ending September 25.

Powered by Capital Market - Live News

The inspection at the Monroe facility was conducted from 9 June to 17 June 2025. Glenmark said that with this positive development, it will restart commercial manufacturing at the facility.

Glenmark Pharmaceuticals is engaged in the business of development, manufacturing, and marketing of pharmaceutical products, both formulations and active pharmaceutical ingredients, to regulated and semi-regulated markets.

Glenmark Pharmaceuticals, the company, reported a 72.3% jump in consolidated net profit to Rs 610.25 crore on a 76.6% increase in revenue from operations to Rs 6,003.79 crore in Q2 FY25.

Powered by Capital Market - Live News